MeiraGTx Holdings plc develops clinical-stage genetic medicines for diseases with high unmet need, with recurring updates centered on AAV gene therapy programs, ocular disease, radiation-induced xerostomia, and regulated gene-expression technology. Company news includes clinical disclosures for AAV-hAQP1 and AAV2-hAQP1 in grade 2/3 radiation-induced xerostomia, ophthalmology programs such as AAV-AIPL1 for Leber congenital amaurosis 4, and the acquired bota-vec program for X-linked retinitis pigmentosa.
Updates also cover strategic collaborations and license agreements, in-house manufacturing capabilities for genetic medicines, riboswitch platform development, operating results, financing arrangements, shareholder voting matters, and capital-structure disclosures tied to MGTX ordinary shares.
MeiraGTx Holdings plc (Nasdaq: MGTX) reported its Q2 financial results for 2021, highlighting significant advancements in its clinical programs. The company's license revenue increased to $5.1 million, up from $2.5 million YoY, partly due to a collaboration with Janssen Pharmaceuticals. R&D expenses decreased to $15.2 million from $16.2 million, while net loss improved to $20.1 million, compared to $25.4 million the previous year. Cash on hand was $172.6 million, providing sufficient capital to sustain operations through Q2 2023. Upcoming trials for XLRP and other indications are set to begin in late 2021.
MeiraGTx Holdings plc (MGTX) reported its Q1 2021 financial results, highlighting a cash position of $199.4 million. The company is advancing its gene therapy programs, with preparations for two Phase 3 trials in X-linked retinitis pigmentosa and RPE65-associated retinal dystrophy. Research and development expenses rose to $16.7 million, up from $8.1 million the previous year, largely due to trial expansions. The net loss increased to $23.6 million, compared to $15.7 million in Q1 2020. MeiraGTx expects sufficient capital to fund operations through mid-2023.
MeiraGTx Holdings (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will speak at several key conferences in May 2021. The events include the BofA Securities 2021 Virtual Health Care Conference on May 12, the RBC Capital Markets Global Healthcare Conference on May 19, and Oppenheimer's Rare & Orphan Disease Summit on May 21. Live webcasts will be available on the Company’s Investors page. MeiraGTx focuses on gene therapies for inherited retinal diseases, neurodegenerative diseases, and severe xerostomia, with multiple programs in clinical development.
MeiraGTx Holdings (Nasdaq: MGTX) will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on April 26, 2021, at 1:45 p.m. ET. The discussion will feature CEO Alexandria Forbes and CDO Stuart Naylor.
A live webcast will be available on the company’s Investors page, and a replay will be accessible for 90 days post-event. MeiraGTx is focused on gene therapy solutions for inherited retinal diseases, neurodegenerative conditions, and xerostomia.
MeiraGTx Holdings announced significant progress in its clinical programs and operational results for 2020. Highlights include positive preliminary data from its Phase 1 AQUAx trial for xerostomia and the upcoming Phase 3 Lumeos trial for AAV-RPGR. The company strengthened its balance sheet with $209 million in cash and extended its cash runway into mid-2023. MeiraGTx also reported a net loss of $58 million for 2020, despite an increase in license revenue from collaborations. The new cGMP plasmid and DNA manufacturing facility adds to their capabilities for clinical development.
MeiraGTx Holdings (Nasdaq: MGTX) announced that CEO Alexandria Forbes will present at the Barclays Global Healthcare Conference on March 11, 2021, at 11:30 a.m. ET. A live webcast will be available on the Company’s investor website, with a replay accessible for 30 days post-presentation.
MeiraGTx is a clinical stage gene therapy company with six clinical programs addressing unmet medical needs in inherited retinal diseases, neurodegenerative diseases, and xerostomia. The company focuses on viral vector design and gene therapy manufacturing.
MeiraGTx Holdings Plc (NASDAQ:MGTX) has announced that the FDA granted Fast Track designation to its AAV-CNGA3 gene therapy for achromatopsia (ACHM) caused by mutations in the CNGA3 gene. This designation facilitates expedited development and review of drugs addressing serious conditions. Currently, MeiraGTx is conducting a Phase 1/2 clinical trial for AAV-CNGA3. This is the third Fast Track designation for the company’s retinal disease products, emphasizing the high unmet medical need for effective therapies in this area.
MeiraGTx Holdings (Nasdaq: MGTX) will hold a webcast and conference call on December 17, 2020, at 8:00 a.m. ET to discuss the AAV-hAQP1 clinical program targeting radiation-induced xerostomia. They will share results from the first cohort of three patients in the Phase 1 AQUAx clinical trial, where one patient exhibited complete symptom resolution at the 12-month mark. The treatment showed good tolerance with no serious adverse effects. This update will feature insights from key presenters, including CEO Alexandria Forbes and trial investigator Dr. Michael Brennan.
MeiraGTx Holdings plc (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 10:05 a.m. ET. The presentation will be available via a live webcast on the company's Investors page. MeiraGTx is a clinical-stage gene therapy company with six programs in development, focusing on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. The company aims to address significant medical needs through innovative gene therapy solutions.
MeiraGTx Holdings plc (Nasdaq: MGTX) announced that Dr. Alexandria Forbes, CEO, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The chat is pre-recorded and accessible on the Company's investor website, with a replay available for 90 days. MeiraGTx is a clinical stage gene therapy company focusing on inherited retinal diseases, neurodegenerative diseases, and xerostomia, with a strong pipeline and innovative gene regulation technology.